Skip to main content
TipRanks
Go Ultimate75% OFF

Lakefront Biotherapeutics (LKFT) Stock Statistics & Valuation Metrics

549 Followers

Total Valuation

Lakefront Biotherapeutics has a market cap or net worth of $2.26B. The enterprise value is -$529.52M.

Market Cap
$2.26B
Enterprise Value
-$529.52M

Share Statistics

Lakefront Biotherapeutics has 65,897,070 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
65,897,070
Owned by Insiders
―
Owned by Institutions
48.20%

Financial Efficiency

Lakefront Biotherapeutics’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 15.40%.

Return on Equity (ROE)
0.10
Return on Assets (ROA)
0.09
Return on Invested Capital (ROIC)
15.40%
Return on Capital Employed (ROCE)
0.15
Revenue Per Employee
2.46M
Profits Per Employee
709.92K
Employee Count
452
Asset Turnover
0.33
Inventory Turnover
1.32

Valuation Ratios

The current PE Ratio of Lakefront Biotherapeutics is 4.24. Lakefront Biotherapeutics’s PEG ratio is -0.11.

PE Ratio
4.24
PS Ratio
1.97
PB Ratio
0.63
Price to FCF
-6.83
Price to Operating Cash Flow
-7.06
PEG Ratio
-0.11

Income Statement

In the last 12 months, Lakefront Biotherapeutics had revenue of 1.11B and earned 320.88M in profits. Earnings per share was 4.87.

Revenue
1.11B
Gross Profit
1.08B
Operating Income
501.39M
Pretax Income
300.87M
Net Income
320.88M
EBITDA
358.96M
Earnings Per Share (EPS)
4.87

Cash Flow

In the last 12 months, operating cash flow was -163.13M and capital expenditures -1.88M, giving a free cash flow of -165.01M billion.

Operating Cash Flow
-163.13M
Free Cash Flow
-165.01M
Free Cash Flow per Share
-4.57

Dividends & Yields

Lakefront Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-14.64%
Earnings Yield
23.68%

Stock Price Statistics

Beta
0.57
52-Week Price Change
12.00%
50-Day Moving Average
30.49
200-Day Moving Average
29.82
Relative Strength Index (RSI)
65.88
Average Volume (3m)
281.34K

Important Dates

Lakefront Biotherapeutics upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 11, 2026
Next Earnings Date
Feb 24, 2027
Ex-Dividend Date
―

Financial Position

Lakefront Biotherapeutics as a current ratio of 20.15, with Debt / Equity ratio of 0.21%

Current Ratio
20.15
Quick Ratio
20.00
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.23
Interest Coverage Ratio
226.16

Taxes

In the past 12 months, Lakefront Biotherapeutics has paid -18.62M in taxes.

Income Tax
-18.62M
Effective Tax Rate
-0.06

Enterprise Valuation

Lakefront Biotherapeutics EV to EBITDA ratio is 5.75, with an EV/FCF ratio of -6.63.

EV to Sales
1.91
EV to EBITDA
5.75
EV to Free Cash Flow
-6.63
EV to Operating Cash Flow
-6.83

Balance Sheet

Lakefront Biotherapeutics has $2.22B in cash and marketable securities with $3.15M in debt, giving a net cash position of $2.22B billion.

Cash & Marketable Securities
$2.22B
Total Debt
$3.15M
Net Cash
$2.22B
Net Cash Per Share
$33.64
Tangible Book Value Per Share
$38.39

Margins

Gross margin is 98.01%, with operating margin of 36.43%, and net profit margin of 46.83%.

Gross Margin
98.01%
Operating Margin
36.43%
Pretax Margin
45.14%
Net Profit Margin
46.83%
EBITDA Margin
33.26%
EBIT Margin
30.70%

Analyst Forecast

The average price target for Lakefront Biotherapeutics is $36.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$36.00
Price Target Upside
5.66% Upside
Analyst Consensus
Moderate Buy
Analyst Count
3
Revenue Growth Forecast
240.77%
EPS Growth Forecast
―

Scores

Smart Score
10
AI Score
69.2